E-LIB Suche - Ergebnisse für: Musey, Luwy K.

1

A phase 3 trial of safety, tolerability, and immunogenicity..:

Platt, Heather L. ; Cardona, Jose F. ; Haranaka, Miwa...
Vaccine. 40 (2022) 1 - p. 162-172 , 2022

Link: https://doi.org/10.1016/..

2

Safety, tolerability, and immunogenicity of V114, a 15-vale..:

Severance, Randall ; Schwartz, Howard ; Dagan, Ron...
Human Vaccines & Immunotherapeutics. 18 (2021) 1 - p. 1-14 , 2021

Link: https://doi.org/10.1080/..

3

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 ..:

Buchwald, Ulrike K. ; Andrews, Charles P. ; Ervin, John...
Human Vaccines & Immunotherapeutics. 17 (2021) 8 - p. 2678-2690 , 2021

Link: https://doi.org/10.1080/..

4

A Phase II Trial of Safety, Tolerability and Immunogenicity..:

Platt, Heather L. ; Greenberg, David ; Tapiero, Bruce...
Pediatric Infectious Disease Journal. 39 (2020) 8 - p. 763-770 , 2020

Link: https://doi.org/10.1097/..

5

Functional Evaluation and Genetic Evolution of Human T-Cell..:

Cox, Kara S ; Zhang, Lu ; Freed, Daniel C...
The Journal of Infectious Diseases. 223 (2020) 11 - p. 2001-2012 , 2020

Link: https://doi.org/10.1093/..

6

Safety and immunogenicity of 15-valent pneumococcal conjuga..:

Ermlich, Susan J. ; Andrews, Charles P. ; Folkerth, Steven...
Vaccine. 36 (2018) 45 - p. 6875-6882 , 2018

Link: https://doi.org/10.1016/..

7

Safety, tolerability, and immunogenicity of 15-valent pneum..:

McFetridge, Richard ; Meulen, Ajoke Sobanjo-ter ; Folkerth, Steven D....
Vaccine. 33 (2015) 24 - p. 2793-2799 , 2015

Link: https://doi.org/10.1016/..

8

M-M-R®II manufactured using recombinant human albumin (rHA)..:

Wiedmann, Richard T. ; Reisinger, Keith S. ; Hartzel, Jonathan...
Vaccine. 33 (2015) 18 - p. 2132-2140 , 2015

Link: https://doi.org/10.1016/..

9

Differences in serious clinical outcomes of infection cause..:

Grabenstein, John D. ; Musey, Luwy K.
Vaccine. 32 (2014) 21 - p. 2399-2405 , 2014

Link: https://doi.org/10.1016/..

10

Human Immunodeficiency Virus-Specific and CD3-Redirected Cy..:

White, Hillary D. ; Musey, Luwy K. ; Andrews, Mary-Margaret...
The Journal of Infectious Diseases. 183 (2001) 6 - p. 977-983 , 2001

Link: https://www.jstor.org/st..

11

Human Immunodeficiency Virus–Specific and CD3‐Redirected Cy..:

White, Hillary D. ; Musey, Luwy K. ; Andrews, Mary‐Margaret...
The Journal of Infectious Diseases. 183 (2001) 6 - p. 977-983 , 2001

Link: https://doi.org/10.1086/..

12

Early and Persistent Human Immunodeficiency Virus Type 1 (H..:

Musey, Luwy K. ; Krieger, John N. ; Hughes, James P....
The Journal of Infectious Diseases. 180 (1999) 2 - p. 278-284 , 1999

Link: https://doi.org/10.1086/..

13

Early and Persistent Human Immunodeficiency Virus Type 1 (H..:

Musey, Luwy K. ; Krieger, John N. ; Hughes, James P....
The Journal of Infectious Diseases. 180 (1999) 2 - p. 278-284 , 1999

Link: https://www.jstor.org/st..

14

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 ..:

Buchwald, Ulrike K ; Andrews, Charles P ; Ervin, John...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475587/. , 2021

Link: http://www.ncbi.nlm.nih...

15

Safety, tolerability, and immunogenicity of V114, a 15-vale..:

Severance, Randall ; Schwartz, Howard ; Dagan, Ron...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920144/. , 2021

Link: http://www.ncbi.nlm.nih...